MYR Group reports Q2 results on July 30 against one of its sharpest drawdowns in recent memory — the stock has shed 29% over the past month to $340.72, including an 8% drop on Tuesday and a 15% slide on the week alone, leaving investors to judge whether the selloff has overshot or whether execution concerns are finally forcing a genuine re-rating.
The lending market offers little comfort to anyone hoping for a short-covering bounce. Short interest is around 4.7% of the free float — not extreme, but it has been easing, down roughly 6% on the week to about 727,000 shares. Borrow costs have fallen sharply too, down 23% on the week to just 0.42%, near the lowest level of the past month. Availability is exceptionally loose at over 1,170% — meaning roughly 12 shares are available to borrow for every one currently lent out, well above the 52-week low of 754%. That picture points clearly in one direction: there is no squeeze dynamic building here. Shorts are not rebuilding aggressively, the borrow market is wide open, and the short score has been drifting lower all week to 38.9, its lowest reading in at least 10 days. Options positioning, however, tells a more defensive story. The put/call ratio is running at 4.08, above its 20-day average of 3.69 and the highest level since late June. That elevated reading has persisted for most of this week, suggesting investors have been actively buying downside protection ahead of tomorrow's print.
The Street entered this week broadly constructive on MYRG, but price targets now look stretched relative to where the stock has landed. The most recent update came from Cantor Fitzgerald in May, which raised its target sharply to $564 following Q1 results — well above current levels. Goldman Sachs maintained Neutral at $296 in March, a target the stock has now blown through on the downside. The mean consensus target of $445.50 implies roughly 31% upside from the current price, though targets were set before a 29% monthly decline and should be treated cautiously until updated post-earnings. Bulls point to a multiyear T&D spending cycle and improved execution after earlier project missteps; bears flag margin pressure from weather, sequencing disruptions, and permitting headaches. Valuation has compressed sharply — the P/E multiple has fallen 13.7 points over the past 30 days to about 27x, and EV/EBITDA has dropped 1.8 turns to 14.8x, reflecting the repricing in real time. The 90-day EPS momentum factor score ranks in the 92nd percentile, and the company has a strong track record of beating estimates (85th percentile on EPS surprise), which sets a high bar.
History from the two most recent earnings prints is striking. After Q1 2026 results on April 30, the stock jumped 28% on day one and extended to 27% over five days. An earlier print — announced the same day on April 29 — produced a 22% one-day gain and a 37% five-day move. Both were dramatic upside reactions following what appears to have been a period of low expectations. The setup heading into Wednesday's report is meaningfully different: the stock peaked above $480 in early June before this month's collapse, insiders were net sellers of roughly $11.8m worth of shares in the 90 days to June 3 — including the CFO and multiple directors selling near $450-$453 — and the stock has now given back all of those post-Q1 gains.
Peer pressure has been broad but MYRG is underperforming its closest rivals. PWR fell 8% on the week and MTZ dropped 11%, so sector-wide weakness is clearly a factor. But ECG and AGX — both down 14% and 14% respectively — suggest the more cyclically exposed names within construction and engineering are bearing the heaviest selling. The key question for tomorrow's call is whether MYRG's margin trajectory in both T&D and C&I has stabilised, or whether the month-long selloff reflects information the Street is only beginning to price in.
See the live data behind this article on ORTEX.
Open MYRG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
